DK1490405T3 - Antagonistiske humane anti-hFas-igand-antistoffer og fragmenter deraf - Google Patents
Antagonistiske humane anti-hFas-igand-antistoffer og fragmenter derafInfo
- Publication number
- DK1490405T3 DK1490405T3 DK03716239T DK03716239T DK1490405T3 DK 1490405 T3 DK1490405 T3 DK 1490405T3 DK 03716239 T DK03716239 T DK 03716239T DK 03716239 T DK03716239 T DK 03716239T DK 1490405 T3 DK1490405 T3 DK 1490405T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- hfasl
- hfas
- human antibodies
- igand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36705402P | 2002-03-21 | 2002-03-21 | |
| US40976802P | 2002-09-10 | 2002-09-10 | |
| PCT/US2003/006155 WO2003079750A2 (en) | 2002-03-21 | 2003-03-12 | ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1490405T3 true DK1490405T3 (da) | 2007-12-27 |
Family
ID=28457146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03716239T DK1490405T3 (da) | 2002-03-21 | 2003-03-12 | Antagonistiske humane anti-hFas-igand-antistoffer og fragmenter deraf |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7262277B2 (pt) |
| EP (1) | EP1490405B1 (pt) |
| JP (1) | JP2005520523A (pt) |
| CN (1) | CN1283662C (pt) |
| AT (1) | ATE370970T1 (pt) |
| AU (1) | AU2003219954B2 (pt) |
| BR (1) | BR0308401A (pt) |
| CA (1) | CA2478386A1 (pt) |
| DE (1) | DE60315815T2 (pt) |
| DK (1) | DK1490405T3 (pt) |
| ES (1) | ES2291626T3 (pt) |
| IL (1) | IL164011A0 (pt) |
| MX (1) | MXPA04009148A (pt) |
| PT (1) | PT1490405E (pt) |
| WO (1) | WO2003079750A2 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| SG10202008722QA (en) | 2003-11-05 | 2020-10-29 | Roche Glycart Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
| CN101014620B (zh) * | 2004-02-06 | 2012-05-09 | 马萨诸塞州大学 | 抗艰难梭菌毒素抗体及其用途 |
| AR055137A1 (es) * | 2005-08-26 | 2007-08-08 | Glycart Biotechnology Ag | Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada |
| EP2231708B1 (en) * | 2007-12-12 | 2015-04-08 | Pincell Srl | Remedies for pemphigus containing anti-fas ligand antibodies |
| EP2318441A2 (en) * | 2008-07-14 | 2011-05-11 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
| JP5773882B2 (ja) * | 2008-12-12 | 2015-09-02 | ピンチェル ソチエタ・レスポンサビリタ・リミタータＰｉｎＣｅｌｌ ｓｒｌ | 抗ＦａｓＬリガンド抗体を含有する天疱瘡用治療薬 |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| JP2016508606A (ja) * | 2013-02-01 | 2016-03-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | トリプルネガティブ乳ガンにおける転移を予測及び予防するための方法 |
| CN105393121B (zh) * | 2013-04-29 | 2018-04-24 | 阿珀吉尼科斯股份公司 | 诊断癌症的方法 |
| EP3137909B1 (en) * | 2014-04-29 | 2018-06-06 | Apogenix AG | Diagnostic anti-cd95l antibody |
| US20220289827A1 (en) * | 2021-03-11 | 2022-09-15 | Washington University | Neutralizing antibodies to sars-cov-2 and its variants |
| WO2023138521A1 (zh) * | 2022-01-21 | 2023-07-27 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| WO2023138522A1 (zh) * | 2022-01-21 | 2023-07-27 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| WO2023208990A1 (en) | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist, |
| WO2024193714A1 (zh) * | 2023-03-23 | 2024-09-26 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
| WO2024200287A1 (en) | 2023-03-24 | 2024-10-03 | Pincell S.R.L. | Anti-fas ligand (fasl) antibodies in the treatment of sjs/ten diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08127594A (ja) | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ |
| JPH09508009A (ja) | 1994-01-07 | 1997-08-19 | イミュネックス・コーポレーション | Ｆａｓ抗原を結合するリガンド |
| US6096312A (en) | 1995-06-30 | 2000-08-01 | Mochida Pharmaceutical Co., Ltd. | Agent for suppressing a reduction of CD4+ lymphocytes |
| US6114507A (en) | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
| CA2225852C (en) * | 1995-06-30 | 2009-04-14 | Mochida Pharmaceutical Co., Ltd. | Anti-fas ligand antibody and assay method using the anti-fas ligand antibody |
-
2003
- 2003-03-12 AT AT03716239T patent/ATE370970T1/de not_active IP Right Cessation
- 2003-03-12 EP EP03716239A patent/EP1490405B1/en not_active Expired - Lifetime
- 2003-03-12 CA CA002478386A patent/CA2478386A1/en not_active Abandoned
- 2003-03-12 AU AU2003219954A patent/AU2003219954B2/en not_active Ceased
- 2003-03-12 DK DK03716239T patent/DK1490405T3/da active
- 2003-03-12 WO PCT/US2003/006155 patent/WO2003079750A2/en active IP Right Grant
- 2003-03-12 JP JP2003577595A patent/JP2005520523A/ja active Pending
- 2003-03-12 PT PT03716239T patent/PT1490405E/pt unknown
- 2003-03-12 MX MXPA04009148A patent/MXPA04009148A/es active IP Right Grant
- 2003-03-12 ES ES03716239T patent/ES2291626T3/es not_active Expired - Lifetime
- 2003-03-12 US US10/506,743 patent/US7262277B2/en not_active Expired - Fee Related
- 2003-03-12 CN CNB038064030A patent/CN1283662C/zh not_active Expired - Fee Related
- 2003-03-12 DE DE60315815T patent/DE60315815T2/de not_active Expired - Lifetime
- 2003-03-12 IL IL16401103A patent/IL164011A0/xx unknown
- 2003-03-12 BR BR0308401-9A patent/BR0308401A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04009148A (es) | 2005-02-28 |
| BR0308401A (pt) | 2005-03-29 |
| CN1283662C (zh) | 2006-11-08 |
| DE60315815D1 (de) | 2007-10-04 |
| EP1490405A4 (en) | 2005-09-14 |
| AU2003219954A1 (en) | 2003-10-08 |
| CA2478386A1 (en) | 2003-10-02 |
| EP1490405B1 (en) | 2007-08-22 |
| CN1642980A (zh) | 2005-07-20 |
| JP2005520523A (ja) | 2005-07-14 |
| AU2003219954B2 (en) | 2006-11-09 |
| WO2003079750A3 (en) | 2004-05-13 |
| DE60315815T2 (de) | 2008-05-21 |
| US20050106140A1 (en) | 2005-05-19 |
| IL164011A0 (en) | 2005-12-18 |
| US7262277B2 (en) | 2007-08-28 |
| ES2291626T3 (es) | 2008-03-01 |
| PT1490405E (pt) | 2007-11-07 |
| ATE370970T1 (de) | 2007-09-15 |
| WO2003079750A2 (en) | 2003-10-02 |
| EP1490405A2 (en) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006740A (es) | Anticuerpos humanos que se unen a la il-12 humana y metodos para producirlos. | |
| DK1490405T3 (da) | Antagonistiske humane anti-hFas-igand-antistoffer og fragmenter deraf | |
| NO2017038I2 (no) | Adalimumab - Forlenget SPC | |
| TW200738749A (en) | Human antibodies that bind human IL-12 and methods for producing | |
| DK1685152T3 (da) | IL-18-bindingsproteiner | |
| NO20062289L (no) | Antigen bindende molekyler med oket FC reseptor bindende affinitet og effektor funksjon | |
| MY146017A (en) | Antibodies that bind human interleukin-18 and methods of making and using | |
| EA201390278A1 (ru) | Антитела к ох40 и способы их применения | |
| WO2003016468A3 (en) | Antagonistic anti-htnfsf13b human antibodies | |
| WO2005016951A3 (en) | Anti-ghrelin fab antibodies | |
| MX2024006573A (es) | Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteinas de fusion il-15. |